<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30376083</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>suppl_1</Issue><PubDate><Year>2018</Year><Month>Oct</Month><Day>30</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Pediatric HIV Infection and Decreased Prevalence of OPV Point Mutations Linked to Vaccine-associated Paralytic Poliomyelitis.</ArticleTitle><Pagination><StartPage>S78</StartPage><EndPage>S84</EndPage><MedlinePgn>S78-S84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciy635</ELocationID><Abstract><AbstractText Label="BACKGROUND">Mutations associated with prolonged replication of the attenuated polioviruses found in oral poliovirus vaccine (OPV) can lead to vaccine-derived poliovirus (VDPV) and cause paralysis indistinguishable from that caused by wild poliovirus. In response, the World Health Organization has initiated the transition to exclusive use of inactivated poliovirus vaccine (IPV), with OPV administration in cases of outbreak. However, it is currently unclear how IPV-only vaccination, well known to provide humoral but not mucosal immunity, will impact the development of paralysis causing OPV variants. Children infected with human immunodeficiency virus (HIV) have been documented to show decreased mucosal immunity following OPV vaccination. Thus, HIV-infected children vaccinated with OPV may serve as proxy for children with IPV-only vaccination.</AbstractText><AbstractText Label="METHODS">We conducted a prospective study of Zimbabwean infants receiving OPV as part of their routine vaccination schedule. Stool samples collected from OPV-vaccinated children serially until age 24 months were tested for OPV serotypes using a real-time polymerase chain reaction protocol that quantifies the amount of mutant OPV variants found in each sample.</AbstractText><AbstractText Label="RESULTS">Out of 2130 stool samples collected from 402 infants 365 stool samples were OPV positive: 313 from 212 HIV-noninfected (HIV-) infants and 52 from 34 HIV-infected (HIV+) infants. HIV- infants showed significantly higher proportions of OPV mutants when compared to HIV+ infants.</AbstractText><AbstractText Label="CONCLUSIONS">HIV infection is associated with a reduced proportion of OPV vaccine associated paralytic polio mutants. These results suggest that OPV administered to individuals previously vaccinated only with IPV will show decreased propensity for OPV mutations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Halpern</LastName><ForeName>Meira S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Stanford School of Medicine, Stanford University, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altamirano</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Stanford School of Medicine, Stanford University, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maldonado</LastName><ForeName>Yvonne</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Stanford School of Medicine, Stanford University, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI068577</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017201" MajorTopicYN="N">Virus Shedding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014944" MajorTopicYN="N">World Health Organization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015030" MajorTopicYN="N" Type="Geographic">Zimbabwe</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30376083</ArticleId><ArticleId IdType="pmc">PMC6206102</ArticleId><ArticleId IdType="doi">10.1093/cid/ciy635</ArticleId><ArticleId IdType="pii">5146680</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Global Polio Eradication Initiative: annual report 2016. Geneva, Switzerland: World Health Organization, 2017. (WHO/Polio/17.03). Licence: CC BY-NC-SA 3.0 IGO.</Citation></Reference><Reference><Citation>
World Health Organization. Polio Global Eradication Initiative
Geneva, Switzerland: World Health Organization, 2017.  [Online]. Available at: http://polioeradication.org/polio-today/polio-now/. Accessed 31 December 2017.</Citation></Reference><Reference><Citation>Hampton LM, Farrell M, Ramirez-Gonzalez A, et al. ; Immunization Systems Management Group of the Global Polio Eradication Initiative Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine&#x2014;worldwide, 2016. MMWR Morb Mortal Wkly Rep 2016; 65:934&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>Okayasu H, Sutter RW, Czerkinsky C, Ogra PL. Mucosal immunity and poliovirus vaccines: impact on wild poliovirus infection and transmission. Vaccine 2011; 29:8205&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">21896299</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt LR, Est&#xed;variz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis 2014; 210(Suppl 1):S380&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10424844</ArticleId><ArticleId IdType="pubmed">25316859</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis 2014; 210(Suppl 1):S283&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316847</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotkin SA, Orenstein WA, Offit PA.. Vaccines. 6th ed. Philadelphia, PA: Elsevier Saunders, 2013.</Citation></Reference><Reference><Citation>Diop OM, Burns CC, Wassilak SG, Kew OM; Centers for Disease Control and Prevention Update on vaccine-derived polioviruses&#x2014;worldwide, July 2012&#x2013;December 2013. MMWR Morb Mortal Wkly Rep 2014; 63:242&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4584635</ArticleId><ArticleId IdType="pubmed">24647401</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddad-Boubaker S, Ben Yahia A, Bahri O, et al. . Genetic features of polioviruses isolated in Tunisia, 1991&#x2013;2006. J Clin Virol 2008; 41:81&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18023246</ArticleId></ArticleIdList></Reference><Reference><Citation>Wassilak S, Pate MA, Wannemuehler K, et al. . Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. J Infect Dis 2011; 203:898&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068031</ArticleId><ArticleId IdType="pubmed">21402542</ArticleId></ArticleIdList></Reference><Reference><Citation>Joffret ML, J&#xe9;gouic S, Bessaud M, et al. . Common and diverse features of cocirculating type 2 and 3 recombinant vaccine-derived polioviruses isolated from patients with poliomyelitis and healthy children. J Infect Dis 2012; 205:1363&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">22457288</ArticleId></ArticleIdList></Reference><Reference><Citation>Gumede N, Lentsoane O, Burns CC, et al. . Emergence of vaccine-derived polioviruses, Democratic Republic of Congo, 2004-2011. Emerg Infect Dis 2013; 19:1583&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3810735</ArticleId><ArticleId IdType="pubmed">24047933</ArticleId></ArticleIdList></Reference><Reference><Citation>Hovi T, Paananen A, Blomqvist S, et al. . Characteristics of an environmentally monitored prolonged type 2 vaccine derived poliovirus shedding episode that stopped without intervention. PLoS One 2013; 8:e66849.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3729856</ArticleId><ArticleId IdType="pubmed">23935826</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor PD. The molecular biology of poliovaccines. J Gen Virol 1992; 73(Pt 12):3065&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">1335021</ArticleId></ArticleIdList></Reference><Reference><Citation>Otelea D, Guillot S, Furione M, et al. . Genomic modifications in naturally occurring neurovirulent revertants of Sabin 1 polioviruses. Dev Biol Stand 1993; 78:33&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8099049</ArticleId></ArticleIdList></Reference><Reference><Citation>Macadam AJ, Pollard SR, Ferguson G, et al. . Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 1993; 192:18&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">8390752</ArticleId></ArticleIdList></Reference><Reference><Citation>Cann AJ, Stanway G, Hughes PJ, et al. . Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Res 1984; 12:7787&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC320200</ArticleId><ArticleId IdType="pubmed">6093054</ArticleId></ArticleIdList></Reference><Reference><Citation>Espa&#xf1;ol T, Garcia X, Caragol I, Sauleda S, Muntane C. Immunological abnormalities in pediatric AIDS. Immunol Invest 1991; 20:215&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">1907598</ArticleId></ArticleIdList></Reference><Reference><Citation>Gnanashanmugam D, Troy SB, Musingwini G, et al. . Immunologic response to oral polio vaccine in human immunodeficiency virus-infected and uninfected Zimbabwean children. Pediatr Infect Dis J 2012; 31:176&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">22146742</ArticleId></ArticleIdList></Reference><Reference><Citation>Troy SB, Musingwini G, Halpern MS, et al. . Vaccine poliovirus shedding and immune response to oral polio vaccine in HIV-infected and -uninfected Zimbabwean infants. J Infect Dis 2013; 208:672&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719901</ArticleId><ArticleId IdType="pubmed">23661792</ArticleId></ArticleIdList></Reference><Reference><Citation>Holubar M, Troy SB, Nathoo K, et al. . Shedding of oral poliovirus vaccine (OPV) by HIV-infected and -uninfected mothers of OPV-vaccinated Zimbabwean infants. J Pediatric Infect Dis Soc 2017; 6:105&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5907849</ArticleId><ArticleId IdType="pubmed">26759497</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization. Treatment of children living with HIV
2017.  [Online]. Available at: http://www.who.int/hiv/topics/paediatric/hiv-paediatric-infopage/en/. Accessed 25 October 2017.</Citation></Reference><Reference><Citation>Troy SB, Ferreyra-Reyes L, Huang C, et al. . Use of a novel real-time PCR assay to detect oral polio vaccine shedding and reversion in stool and sewage samples after a Mexican national immunization day. J Clin Microbiol 2011; 49:1777&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122635</ArticleId><ArticleId IdType="pubmed">21411577</ArticleId></ArticleIdList></Reference><Reference><Citation>Gnanashanmugam D, Falkovitz-Halpern MS, Dodge A, et al. . Shedding and reversion of oral polio vaccine type 3 in Mexican vaccinees: comparison of mutant analysis by PCR and enzyme cleavage to a real-time PCR assay. J Clin Microbiol 2007; 45:2419&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1951214</ArticleId><ArticleId IdType="pubmed">17581940</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez C, Old MO, Kwock DK, et al. . Shedding of Sabin poliovirus type 3 containing the nucleotide 472 uracil-to-cytosine point mutation after administration of oral poliovirus vaccine. J Infect Dis 2004; 190:409&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">15216480</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization. Polio Eradication &amp; Endgame Strategic Plan 2013&#x2013;2018
2013.  [Online]. Available at: http://polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_US.pdf. Accessed 16 November 2017.</Citation></Reference><Reference><Citation>
World Health Organization. OPV [Online]. Available at: http://polioeradication.org/polio-today/polio-prevention/the-vaccines/opv/. Accessed 16 August 2017.</Citation></Reference><Reference><Citation>Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathogens 2012; 8:e1002599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3330118</ArticleId><ArticleId IdType="pubmed">22532797</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker EP, Molodecky NA, Pons-Salort M, O&#x2019;Reilly KM, Grassly NC. Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame. Expert Rev Vaccines 2015; 14:1113&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4673562</ArticleId><ArticleId IdType="pubmed">26159938</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>